Related Experiment Videos
Evaluation of in vitro drug screening leads using experimental models of human ovarian cancer
K G Louie1, T C Hamilton, R H Shoemaker
1Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892.
Abstract:
Five compounds which were identified as potential new anticancer drugs in in vitro screening with the human tumor colony forming assay were selected for further evaluation using in vitro and in vivo models of human ovarian cancer. Three of five compounds were found to inhibit in vitro colony formation of ovarian cancer cell lines derived from both untreated and combination chemotherapy refractory patients. One compound was also found to prolong survival in a human ovarian carcinoma xenograft model system. This compound, chloroquinoxaline sulfonamide, was selected for development and has shown preliminary indication of activity in phase I clinical testing.
Insights
Researchers identified potential anticancer drugs for ovarian cancer. One compound, chloroquinoxaline sulfonamide, inhibited cancer cell growth and prolonged survival in animal models, showing promise in early human trials.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Developing novel anticancer therapeutics is crucial for treating human ovarian cancer.
- Identifying compounds effective against both treatment-naive and chemotherapy-refractory ovarian cancer remains a significant challenge.
Purpose of the Study:
- To evaluate five promising compounds identified through in vitro screening for their efficacy in ovarian cancer models.
- To identify and advance a lead compound for further preclinical and clinical development.
Main Methods:
- In vitro evaluation using human ovarian cancer cell lines (chemotherapy-sensitive and resistant).
- In vivo assessment in a human ovarian carcinoma xenograft mouse model.
- Clinical evaluation in Phase I human trials.
Main Results:
- Three of the five tested compounds demonstrated inhibition of in vitro colony formation in ovarian cancer cell lines.
- One compound significantly prolonged survival in a human ovarian carcinoma xenograft model.
- Chloroquinoxaline sulfonamide showed preliminary activity in Phase I clinical testing.
Conclusions:
- Chloroquinoxaline sulfonamide is a promising candidate for ovarian cancer treatment.
- Further clinical investigation of chloroquinoxaline sulfonamide is warranted based on preclinical and early clinical data.